1. Home
    2. About Praluent®
    3. Dosing

    New 4-weekly (monthly) single injection

    An option for your patients who require an LDL-C reduction of >60%1

    300 mg Q4W

    A device you’ll recognise with one step less2,3

    • No button to push
    • Injection starts when device is pressed fully into the skin
    • Designed to deliver once-monthly dose in ≤20 seconds4

    Only PCSK9i with once-monthly single injection in a pre-filled pen1

    • The potential to halve the administration days for your patients

    Two twice-monthly options1

    75 mg Q2W*

    *Recommended starting dose.

    150 mg Q2W

    The usual starting dose for Praluent® is 75 mg administered subcutaneously Q2W. Patients requiring larger LDL-C reduction (>60%) may be started on 150 mg Q2W, or 300 mg Q4W (monthly), administered subcutaneously.

    Customised treatment with Praluent®

    Dosage information

    The dose of Praluent® can be individualised based on patient characteristics such as baseline LDL-C level, goal of therapy, and response. Lipid levels can be assessed 4 to 8 weeks after treatment initiation or titration, and dose adjusted accordingly (up-titration or down-titration). If additional LDL-C reduction is needed in patients treated with 75 mg Q2W or 300 mg once Q4W (monthly), the dosage may be adjusted to the maximum dosage of 150 mg Q2W.

    If a dose is missed, the patient should administer the injection as soon as possible and thereafter resume treatment on the original schedule.

    PRALUENT INDICATION

    Learn more

    PATIENT RESOURCES

    Learn more

    Footnotes & references

    For full instructions on use refer to the Patient information Leaflet

    CV=cardiovascular; LDL-C=low-density lipoprotein cholesterol; Q2W=once every two weeks; Q4W=once every four weeks.

    1. Praluent Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/medicine/30956. Accessed April 2021.
    2. Praluent Patient information leaflet 150mg. November 2020.
    3. Praluent Patient information leaflet 300mg. November 2020.
    4. Frias JP, Koren MJ, Loizeau V, et al. The SYDNEY Device Study: A Multicenter, Randomized, Open-label Usability Study of a 2-mL Alirocumab Autoinjector Device. Clinical Therapeutics. 2020; 42(1):94-107.